November 21, 2017 / 1:16 PM / 7 months ago

BRIEF-Catalyst Pharmaceuticals ‍announces phase 2 study of Firdapse

* Announces phase 2 study of Firdapse in ambulatory patients with spinal muscular atrophy​

* Anticipates reporting top-line results from study in first half of 2019 for Firdapse​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below